NAD+ salvage is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Abbreviated NMN |
| Molecular formula | C11H15N2O8P | Neutral form |
| Molar mass | 334.22 g/mol | Approximate value |
| Appearance | White to off-white powder | Typical solid form |
| Solubility | Water-soluble | May absorb moisture |
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
=== February === 1 February A ban on owning an American XL Bully dog comes into force in England and Wales. It is now a criminal offence to own one of the dogs unless the owner has successfully applied for the dog to be exempt. The Bank of England holds interest rates at 5.25%. Climate activist Greta Thunberg appears at Westminster Magistrates' Court, charged with breaching section 14 of the Public Order Act 1986. Her case, and that of four co-defendants, is thrown out the following day. COVID-19 vaccination in the United Kingdom: The first private service for COVID-19 vaccination begins rolling out to pharmacies around the UK, allowing those who are under 65 to receive the latest booster. 2 February Senior Labour MP Darren Jones confirms that the party has ditched its commitment to spend £28bn a year on green investment schemes if it wins the next general election. The killers of 16-year-old transgender girl Brianna Ghey are named as Scarlett Jenkinson and Eddie Ratcliffe, both aged 15 at the time of the murder in February 2023. They are sentenced at Manchester Crown Court to minimum terms of 22 and 20 years, respectively. Water UK, the umbrella trade organisation for the UK's water companies, says that the average annual water bill is expected to increase by 6% in England and Wales from April, an average rise of £27 to £473. 3 February 2024 Northern Ireland Executive formation: The Northern Ireland Assembly meets to elect a new Speaker. Edwin Poots, a former leader of the DUP, is chosen to be the Assembly's 7th Speaker.
About 20,000 protein coding genes are expressed in human cells and almost 75% of these genes are expressed in the normal lung. A little less than 200 of these genes are more specifically expressed in the lung with less than 20 genes being highly lung specific. The highest expression of lung specific proteins are different surfactant proteins, such as SFTPA1, SFTPB and SFTPC, and napsin, expressed in type II pneumocytes. Other proteins with elevated expression in the lung are the dynein protein DNAH5 in ciliated cells, and the secreted SCGB1A1 protein in mucus-secreting goblet cells of the airway mucosa.
== Province-wide expansion and termination == In May 2022, Alberta Health Services signed a 15-year contract valued at approximately $4.8 billion with DynaLIFE to provide community laboratory services across Alberta. Province-wide service delivery began in December 2022. In August 2023, eight months after the transition, Alberta Health Services terminated the agreement at the request of DynaLIFE's owners and transferred the company's Alberta operations to Alberta Precision Laboratories. A 2025 examination by the Auditor General of Alberta found breakdowns in governance, due diligence, risk assessment and financial analysis. The examination found that the Minister and Department of Health expected Alberta Health Services to proceed despite concerns about projected savings, pressures associated with the COVID-19 pandemic and the presence of only one remaining bidder. Neither Alberta Health Services nor the Department of Health completed the required business case, and Alberta Health Services did not adequately evaluate the assumptions underlying DynaLIFE's financial proposal. The examination also found that Alberta Health Services and DynaLIFE proceeded with the transition while essential requirements, including laboratory information-system readiness, remained incomplete. A lack of shared operational planning contributed to increased wait times and diagnostic errors, and an above-average number of pathology-result errors compromised patients. The Auditor General attributed $77 million in non-value-added costs to the unsuccessful outsourcing initiative.
== Possible biological activities == In vitro studies have shown that alkylresorcinols may prevent cells turning cancerous, but that they do not have any effect on cells that are already cancerous. Alkylresorcinols also increase gamma-tocopherol levels in rats when fed in high amounts (0.2% of total diet and above). The alkylresorcinols in Grevillea banksii and Grevillea 'Robyn Gordon' are responsible for contact dermatitis.
=== Injury === When traumatic forces of occlusion are placed on a tooth, the PDL widens to take the extra forces. Thus, early occlusal trauma can be viewed on radiographs as a widening of the periodontal ligament space. Thickening of the lamina dura in response is also possible. Clinically, occlusal trauma is noted by the late manifestation of increased mobility of the tooth and possibly the presence of pathological tooth migration. Damage to the PDL may result in tooth ankylosis to the jawbone, making the tooth lose its continuous eruption ability. Dental trauma, such as subluxation, may cause tearing of the PDL and pain during function (eating). The PDL cells of an avulsed tooth are at risk of drying and desiccation if left in dry storage. Wet storage in an isotonic liquid, although a superior method to dry storage, can preserve PDL vitality depending on the medium but not for an indefinite period of time. All of these can lead to loss of vitality of the PDL and depending on the duration of storage, this can affect the success of subsequent replantation.
Sources: en.wikipedia.org
== Chemical composition == The flavonol miquelianin, as well as the alkaloids (+)-(1R)-coclaurine and (−)-(1S)-norcoclaurine, can be found in the leaves of N. nucifera. The plant also contains nuciferine, neferine, and many other benzylisoquinoline alkaloids with medicinal properties.
1 March to August 1971 In the DMZ Campaign (1969-71) the 1st Brigade, 5th Infantry Division (Mechanized) assumed responsibility for the defense of the DMZ from the 3rd Marine Division as it withdrew from South Vietnam.
== Carryover effect in clinical laboratory == Carryover experiments are widely used for clinical chemistry and immunochemistry analyzers to evaluate and validate carryover effects. The pipetting and washing systems in an automated analyzer are designed to continuously cycle between the aspiration of patient specimens and cleaning. An obvious concern is a potential for carryover of analyte from one patient specimen into one or more following patient specimens, which can falsely increase or decrease the measured analyte concentration. Specimen carryover is typically addressed by judicious choice of probe material, probe design, and an efficient probe washing system to flush the probe of residual patient specimens or reagents retained in their bores or clinging to the probe exterior surface before they are introduced into the next patient sample, reagent container, or cuvette/reaction vessel.
=== Birth control === CPA is used with ethinylestradiol as a combined birth control pill to prevent pregnancy. This birth control combination has been available since 1978. The formulation is taken once daily for 21 days, followed by a 7-day free interval. CPA has also been available in combination with estradiol valerate (brand name Femilar) as a combined birth control pill in Finland since 1993. High-dose CPA tablets have a contraceptive effect and can be used as a form of birth control, although they are not specifically licensed as such.
Sources: en.wikipedia.org
=== Clinical and translational applications === Much of this methodological work feeds directly into clinical practice: Borchers' laboratory has applied targeted mass spectrometry to cancer biomarkers and precision oncology, and to other clinical questions, including a 2024 study characterizing the proteomic changes from acute to post-acute (long) COVID-19. His group has also investigated targeted proteomics for anti-doping applications, including a project funded by the Partnership for Clean Competition that used longitudinal blood-protein profiling to screen for blood doping. From 2012 he was one of three project leaders, with Andrew Penn and Shelagh Coutts, on a $9.6 million Genome Canada large-scale applied research project that sought to develop a rapid, inexpensive blood test to distinguish transient ischaemic attacks from conditions that mimic them and reduce reliance on neuroimaging. The project produced an electronic triage tool that came into clinical use on Vancouver Island, alongside work on candidate protein biomarkers.
=== Scope and related laser-based procedures === LANAP is commonly described as a wavelength-dependent, flapless periodontal pocket treatment protocol performed with an Nd:YAG laser (1064 nm). Other minimally invasive or adjunctive laser approaches to periodontal and peri-implant pocket therapy using different wavelengths have been described and are distinct from LANAP. A review reports that CO2 laser systems share soft-tissue applications with diode and Nd:YAG lasers (bacterial reduction, debridement in pockets and around implants, and coagulation), but that clinical studies and meta-analyses have not consistently shown statistically significant improvements versus mechanical debridement alone. For peri-implant diseases, an AAP best-evidence review and meta-analysis reported that laser therapy in combination with surgical or non-surgical therapy provided minimal benefit for several clinical outcomes, and noted that the controlled evidence included in the analyses was limited to Er:YAG, CO2 laser, and diode lasers. In 2016, the FDA cleared labeling for an Nd:YAG system that included an indication describing “promotion of true regeneration” (new cementum, periodontal ligament, and alveolar bone) when used specifically in the LANAP protocol. A 2017 review concluded that studies of lasers in the treatment of periodontitis had not provided sufficient evidence that laser use provides benefit over traditional therapy.
SPECIAL obtains spatial localization from only a single dimension with pre-excitation inversion pulses (cycled on and off every other repetition time [TR]), making it a two-cycle sequence. The use of the preinversion pulse to remove one refocusing pulse (as compared with PRESS) is what allows SPECIAL to achieve a short TE, reaching a minimum of 2.2 msec on a preclinical scanner in rat brain while being able to recover the full signal and as low as 6 msec on a clinical 3T scanner. The largest drawback of SPECIAL and SPECIAL-sLASER is that they are two-cycle schemes, and systematic variations between cycles will manifest in their difference spectrum. Lipid contamination is a particularly large problem with SPECIAL and similar sequences. The state-of-the-art localization sequence is sLASER, which utilizes two pairs of adiabatic refocusing pulses. This has recently been recommended by consensus. The first is through OVS, which will reduce the contamination of lipid signals that originate from outside the voxel, although this comes at the cost of an increase in SAR. The second is not to set the amplitude of the pre-excitation inversion pulse to zero every other TR, but instead to shift the location of this ISIS plane such that the excited volume for the off condition is outside the object. This has been shown to greatly reduce lipid contamination, speculated to have arisen from the interaction between the RF pulse and lipid compartments due to incomplete relaxation, magnetization transfer, or the homonuclear Overhauser effect, although the exact mechanism remains unknown.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.
No. NMN is a precursor that can be converted into NAD+, while NAD+ is a dinucleotide coenzyme involved in redox reactions and signaling.
Small amounts have been reported in foods such as edamame, avocado, broccoli, and milk. Dietary amounts are generally much lower than those used in research studies.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It consists of nicotinamide, ribose, and phosphate groups.